Impacts of the COVID‐19 pandemic on pharmaceuticals in wastewater treated for beneficial reuse: Two case studies in central Pennsylvania. Issue 5 (5th September 2022)

• Record Type: Journal Article
• Authors: Hayden, Kathryn R.; Jones, Matthew; Elkin, Kyle R.; Shreve, Michael J.; Clees, William Irvin; Clark, Shirley; Mashtare, Michael L.; Veith, Tamie L.; Elliott, Herschel A.; Watson, John E.; Silverman, Justin; Richard, Thomas L.; Read, Andrew F.; Preisendanz, Heather E.
• Is Part Of: Journal of Environmental Quality. Volume 51:Issue 5(2022)
• Page Start: 1066
• Page End: 1082
• Publication Date: 2022-09-05
• Subjects: Agricultural ecology -- Periodicals; Environmental engineering -- Periodicals; Pollution -- Periodicals; 630
• DOI: 10.1002/jeq2.20398
• Languages: English
• ISSNs: 0047-2425

Abstract

Abstract: During the COVID‐19 pandemic, wastewater surveillance was leveraged as a powerful tool for monitoring community‐scale health. Further, the well‐known persistence of some pharmaceuticals through wastewater treatment plants spurred concerns that increased usage of pharmaceuticals during the pandemic would increase the concentrations in wastewater treatment plant effluent. We collected weekly influent and effluent samples from May 2020 through May 2021 from two wastewater treatment plants in central Pennsylvania, the Penn State Water Reclamation Facility and the University Area Joint Authority, that provide effluent for beneficial reuse, including for irrigation. Samples were analyzed for severe acute respiratory syndrome coronavirus 2 (influent only), two over‐the‐counter medicines (acetaminophen and naproxen), five antibiotics (ampicillin, doxycycline, ofloxacin, sulfamethoxazole, and trimethoprim), two therapeutic agents (remdesivir and dexamethasone), and hydroxychloroquine. Although there were no correlations between pharmaceutical and virus concentration, remdesivir detection occurred when the number of hospitalized patients with COVID‐19 increased, and dexamethasone detection co‐occurred with the presence of patients with COVID‐19 on ventilators. Additionally, Penn State decision‐making regarding instruction modes explained the temporal variation of influent pharmaceutical concentrations, with detection occurring primarily when students were on campus. Risk quotients calculated for pharmaceuticals with known effective and lethal concentrations at which 50% of a population is affected for fish, daphnia, and algae were generally low in the effluent; however, some acute risks from sulfamethoxazole were high when students returned to campus. Remdesivir and dexamethasone persisted through the wastewater treatment plants, thereby introducing novel pharmaceuticals directly to soils and surface water. These results highlight connections between human health and water quality and further demonstrate the broad utility of wastewater surveillance. Core Ideas: Pharmaceuticals were monitored at two wastewater treatment plants through the COVID‐19 pandemic. Novel pharmaceuticals persisted in reclaimed wastewater for irrigation activities. Detection of dexamethasone occurred with increasing numbers of patients COVID‐19 on ventilators. Pharmaceuticals in effluent posed potential acute risks to nontarget aquatic organisms.